Author/Editor
Chris Wood and Jake Weber
Publisher
Mauldin Economics
Description
High-end newsletter focused on small-cap biotech stocks, using what they call their CASH system to select recommended stocks (Catalysts, large Addressable market, good Science, and a potential Hype story). Wood also edits the “entry level” healthcare investment advisory Healthy Returns.
Overall Rating
Rating: 2.9/5. From 10 votes.
Please wait...
3.1
Rating from 34 votes
If you’ve subscribed to Biotech Millionaire, please click the stars below to indicate your rating for this newsletter, and please share any other feedback about your experience using the comment box below.
Investment Performance
Rating from 9 votes
Rating: 2.9/5. From 9 votes.
Please wait...
Your vote
- 5 Stars 2 Votes
- 4 Stars 1 Votes
- 3 Stars 3 Votes
- 2 Stars 0 Votes
- 1 Stars 3 Votes
Quality Of Writing/Analysis
Rating from 6 votes
Rating: 3.8/5. From 6 votes.
Please wait...
Your vote
- 5 Stars 3 Votes
- 4 Stars 1 Votes
- 3 Stars 0 Votes
- 2 Stars 2 Votes
- 1 Stars 0 Votes
Value For Price
Rating from 9 votes
Rating: 2.8/5. From 9 votes.
Please wait...
Your vote
- 5 Stars 1 Votes
- 4 Stars 3 Votes
- 3 Stars 1 Votes
- 2 Stars 1 Votes
- 1 Stars 3 Votes
Customer Service
Rating from 10 votes
Rating: 2.9/5. From 10 votes.
Please wait...
Your vote
- 5 Stars 1 Votes
- 4 Stars 4 Votes
- 3 Stars 0 Votes
- 2 Stars 3 Votes
- 1 Stars 2 Votes
Can someone identify the name of this new stem cell drug that can treat stroke up to 36hrs?
So disappointed with my subscription to Biotech Millionaire. Most recommebdations crashed. Got out after a year and giving it a fair shot. Lost money on most buy recommendations.